Search - tctmd.com

Displaying 41 - 60 of 221

Sort: Relevancy | Date

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisiran, and Bempedoic Acid

Presentation TCT 2023

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

Presenter: Karol Watson

October 26, 2023

Presentation TCT 2023

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

Presenter: Sanjit Jolly

October 25, 2023

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Todd Neale

September 19, 2023

News Daily News

High-risk Plaques in Nonculprit Lesions Tied to Worse Post-MI Outcomes

Caitlin E. Cox

September 18, 2023

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Conference News ADA 2023

Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention

Michael O'Riordan

June 28, 2023

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

News Daily News

Lipid Panels in Standard Precath Blood Draws? Researchers Say It’s Time

Todd Neale

June 13, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Conference News EAS 2023

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

Michael O'Riordan

May 26, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

News Conference News CRT 2023

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

Yael L. Maxwell

March 01, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

Advertisement

What’s Going to Be Hot at AHA 2023

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

High-risk Plaques in Nonculprit Lesions Tied to Worse Post-MI Outcomes

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

LDL Control Remains Poor in CAD Patients: NHANES

Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Lipid Panels in Standard Precath Blood Draws? Researchers Say It’s Time

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content